JO3088B1 - مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف - Google Patents

مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف

Info

Publication number
JO3088B1
JO3088B1 JOP/2005/0188A JOP20050188A JO3088B1 JO 3088 B1 JO3088 B1 JO 3088B1 JO P20050188 A JOP20050188 A JO P20050188A JO 3088 B1 JO3088 B1 JO 3088B1
Authority
JO
Jordan
Prior art keywords
alkyl
alkyloxy
hydrogen
5alkyl
2alkyl
Prior art date
Application number
JOP/2005/0188A
Other languages
English (en)
Inventor
Papanikos Alexandra
Jean Edgard Freyne Eddy
Ten Holte Peter
Henri Storck Pierre
Sophie Poncelet Virginie
Willems Marc
Constant Johan Embrechts Werner
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3088B1 publication Critical patent/JO3088B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات ( compounds) من الصيغه باشكال N- اوكسيد( N-oxide forms) باملاح الاضافة( addition salts) المقبولة دوائيا وبالاشكال الايزومرية الكيميائية الفراغية ( stereochemically isomeric forms) منها حيث: Z يمثل NH Y يمثل C3-9 الكيل( C3-9alkyl) ، c1-5 الكيل C1-5NR13 الكيل، ( C1-5alkyl – NR13-C1-5alkyl) C1-5 الكيل C1-5-CO-NR14 الكيل- ( C1-5alkyl –NR14-CO-C1-5alkyl) C1-2 الكيل C1-3 NH-CO-CH2-NR21 الكيل – (C1-2ALKYL-NR21-CH2-CO-NH-C1-3alkyl) او C1-2 الكيل NH-CR16R17-CO-NR23 ) (C1-2alkyl-NR23-CO-CR16R17-NH X1 يمثل O او C1-2 O الكيل( O-C1-2alkyl-) X2 يمثل رابطة مباشرة ( direct bond) C1-2 الكيل ( C1-2alkyl)، c1-2 co الكيل ( -CO-C1-2alkyl) او C1-2NR12 الكيل ( NR12C1-2alkyl) R1 يمثل هيدروجين ( hydrogen ) او هالو ( halo) R2 يمثل هالو ( halo) استيلين ( acetylene) او Het1 R3 يمثل هيدروجين ( hydrogen) او سيانو ( cyano) R4 يمثل C1-4-Ar4 الكيل اوكسي ( Ar4-C1-4alkoxy) C1-4 الكيل اوكسي (C1-4alkoxy) او C1-4 الكيل اوكسي (C1-4alkoxy) مستبدل مع بديل واحد او اذا امكن مع اثنين او اكثر من بدائل مختراة من Het2 ، NR7R8 هيدروكسي ( hydroxy) و C1-4 الكيل اوكسي C1-4 الكيل اوكسي ( C1-4alkyloxy – C1-4alkyoxy) R7 يمثل هيدروجين ( hydrogen) او c1-4 الكيل( C1-4 alkyl) R8 يمثل c1-4 الكيل( c1-4alkyl) مستبدل مع NR25R26 او C1-4 الكيل سلفونيل ( C1-4 alkylsulfonyl ) R12 يمثل هيدرويجين ( hydrogen) او C1-4 الكيل –( C1-4 alkyl) R13 يمثل AR6 سلفونيل ( AR6-sulfonyl) او C1-6 الكيل اوكسي كربونيل ( C1-6 alkyloxycarbonyl) مستبدل اختياريا مع فنيل ( phenyl) R16 و R17 يمثلان هيدروجين ( hydrogen) C1-4 الكيل( C1-4 alkyl) او يؤخذ R16 و R17 معا مع ذرة الكربون ( carbon atom) المرتبطة معها لتشكيل C3-6 الكيل دائري( C3-6 cycloakyl) R23 يمثل c1-4 الكيل ( C1-4alkyl) و R23 يمثل هيدروجين ( hydrogen) عنما يؤخذ r16 و r17 معا مع ذرة الكربون ( carbon atom) المرتبطة معهما لتشكيل c3-6 الكيل دائري ( C3-6cycloalkyl) R27,R26,R25 و R28 كل منهم على حدة يمثل هيدروجين ( hydrogen) او C1-4 الكيل كربونيل( C1-4alkylcarbonyl) Het1 يمثل 2- بورا-1، 3 ثنائي اوكسولانيل( 2-boro 1.3-dioxolanyl) Het2 يمثل بيبريدينيل ( piperidiny
JOP/2005/0188A 2004-12-08 2005-11-28 مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف JO3088B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04106383 2004-12-08

Publications (1)

Publication Number Publication Date
JO3088B1 true JO3088B1 (ar) 2017-03-15

Family

ID=34930015

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2005/0188A JO3088B1 (ar) 2004-12-08 2005-11-28 مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف

Country Status (22)

Country Link
US (1) US20100152174A1 (ar)
EP (1) EP1828201B1 (ar)
JP (1) JP5140431B2 (ar)
KR (1) KR101320431B1 (ar)
CN (2) CN102532163B (ar)
AR (1) AR051985A1 (ar)
AU (1) AU2005313350B2 (ar)
BR (1) BRPI0518394B8 (ar)
CA (1) CA2588764C (ar)
DK (1) DK1828201T3 (ar)
EA (1) EA013995B1 (ar)
ES (1) ES2559305T3 (ar)
HU (1) HUE027253T2 (ar)
JO (1) JO3088B1 (ar)
MX (1) MX2007006820A (ar)
MY (1) MY148503A (ar)
NZ (1) NZ555496A (ar)
PA (1) PA8654501A1 (ar)
SI (1) SI1828201T1 (ar)
TW (2) TWI511970B (ar)
UA (1) UA91522C2 (ar)
WO (1) WO2006061417A2 (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
DE602004012891T2 (de) 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
DK2044084T3 (en) * 2006-07-13 2016-05-09 Janssen Pharmaceutica Nv MTKI-quinazoline derivatives
MX2009004438A (es) * 2006-10-27 2009-05-11 Janssen Pharmaceutica Nv Uso de inhibidores cinasa de objetivos multiples 1 para tratar o prevenir cancer de hueso.
JP2010507626A (ja) * 2006-10-27 2010-03-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｖｅｇｆｒ３阻害剤としての大環状キナゾリン誘導体
DK2170827T3 (da) * 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
DK2185562T3 (en) * 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
HRP20140309T1 (hr) 2008-10-22 2014-05-09 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
US9499532B2 (en) * 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423536A1 (de) * 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4160836A (en) * 1976-05-17 1979-07-10 Janssen Pharmaceutica N.V. Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives
US4442278A (en) * 1981-12-03 1984-04-10 Hughes Aircraft Company Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
PL182124B1 (pl) * 1993-12-07 2001-11-30 Lilly Co Eli Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
EP0789718B1 (en) * 1994-10-31 1998-04-08 Dsm N.V. Catalyst composition and process for the polymerization of an olefin
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EA199800372A1 (ru) * 1995-11-14 1998-10-29 Дзе Дюпон Мерк Фармасьютикал Компани Новые макроциклические соединения-ингибиторы
DE19608588A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP3370340B2 (ja) * 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
JP3952369B2 (ja) * 1999-08-27 2007-08-01 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な置換インドリノン類、その製造及びその薬剤としての使用
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
WO2002100399A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US7501516B2 (en) * 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60327323D1 (de) * 2002-07-09 2009-06-04 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US20050021480A1 (en) * 2003-05-16 2005-01-27 Hyperspace Communications, Inc. Method and apparatus for creating and validating an encrypted digital receipt for third-party electronic commerce transactions
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
DE602004012891T2 (de) * 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
ATE446750T1 (de) * 2003-12-18 2009-11-15 Janssen Pharmaceutica Nv 3-cyano-chinolin-derivate mit antiproliferativer wirkung
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
BRPI0612888B8 (pt) * 2005-06-30 2022-12-27 Janssen Pharmaceutica Nv anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica
ES2506040T3 (es) * 2005-11-16 2014-10-13 Cti Biopharma Corp. Derivados de pirimidina ligados a oxígeno
DK2044084T3 (en) * 2006-07-13 2016-05-09 Janssen Pharmaceutica Nv MTKI-quinazoline derivatives
DK2170827T3 (da) * 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
DK2185562T3 (en) * 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
DK2283024T3 (da) * 2008-03-10 2013-08-05 Janssen Pharmaceutica Nv 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer

Also Published As

Publication number Publication date
EP1828201B1 (en) 2015-11-11
WO2006061417A3 (en) 2006-08-03
EP1828201A2 (en) 2007-09-05
SI1828201T1 (sl) 2016-02-29
DK1828201T3 (en) 2016-02-01
NZ555496A (en) 2011-04-29
ES2559305T3 (es) 2016-02-11
US20100152174A1 (en) 2010-06-17
EA013995B1 (ru) 2010-08-30
HUE027253T2 (en) 2016-08-29
MX2007006820A (es) 2007-07-24
KR101320431B1 (ko) 2013-10-30
CA2588764A1 (en) 2006-06-15
MY148503A (en) 2013-04-30
CN101072781B (zh) 2012-07-18
TW200635933A (en) 2006-10-16
BRPI0518394B1 (pt) 2020-12-15
WO2006061417A2 (en) 2006-06-15
TWI432440B (zh) 2014-04-01
CN102532163A (zh) 2012-07-04
TW201410684A (zh) 2014-03-16
TWI511970B (zh) 2015-12-11
JP2008523034A (ja) 2008-07-03
PA8654501A1 (es) 2006-09-08
AU2005313350B2 (en) 2012-05-31
AU2005313350A1 (en) 2006-06-15
AR051985A1 (es) 2007-02-21
JP5140431B2 (ja) 2013-02-06
CN102532163B (zh) 2016-06-01
BRPI0518394A2 (pt) 2008-11-18
CA2588764C (en) 2016-11-29
UA91522C2 (en) 2010-08-10
EA200701233A1 (ru) 2007-10-26
KR20070086030A (ko) 2007-08-27
BRPI0518394B8 (pt) 2021-05-25
CN101072781A (zh) 2007-11-14

Similar Documents

Publication Publication Date Title
MY148503A (en) Mtki quinazoline derivatives
WO2007003525A3 (en) Cyclic anilino-pyridinotriazines as gsk-3 inhibitors
CY1121051T1 (el) Περιεχουσα αζωτο ετεροκυκλικη ενωση και γεωργικο/κηπουρικο σποριοκτονο
CY1111266T1 (el) Παραγωγα ετεροκυκλικου αμιδιου χρησιμα ως μικροβιοκτονα
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
NO20063323L (no) Pyrido- og pyrimidopyrimidinderivater
AR068967A1 (es) Compuestos de ciclohexandiona, proceso para la preparacion de los mismos, compuestos intermediarios, metodo de control de hierbas y malezas, y composicion herbicida
EA200501045A1 (ru) Адамантилацетамиды как ингибиторы 11-бета гидроксистероиддегидрогеназы
UA98116C2 (ru) Изоксазолины, композиция, их применение, способы получения и промежуточные соединения
MX2009008325A (es) Herbicidas con n-oxido de piridina sustituido.
HRP20080113T3 (hr) Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane
WO2012080284A3 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
TN2012000033A1 (en) Mixtures of mesoionic pesticides
CR8986A (es) Isoxazoles sustituidos como fungicidas
AR074782A1 (es) Antranilamidas sustituidas con tetrazol como plaguicidas
TW200635931A (en) 2,4(4,6)pyrimidine derivatives
AR059925A1 (es) Formulaciones
TW200502225A (en) Heterocyclic compounds useful as nurr-1 activators
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
PE20070041A1 (es) Amidas de acido pirazolcarboxilico
ATE510820T1 (de) Alkoxy-polyester-verbindungen, zusammensetzungen und verwendungsverfahren dafür
MY136824A (en) Substituted benzoxazinones and uses thereof
EA201070817A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
WO2009027626A3 (en) Improvements in or relating to organic compounds
WO2007061966A3 (en) Amidinylphenyl compounds and their use as fungicides